Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics reported positive topline results from the Phase 3 HAELO trial of lonvo-z, demonstrating an 87% reduction in HAE attacks compared to placebo. The trial met all key secondary endpoints, with 62% of patients remaining attack- and therapy-free over six months and no serious adverse events observed in the treatment arm. Based on these results, the company initiated a rolling BLA submission to the FDA and targets a potential U.S.
Key figures
- Drug Name
- lonvoguran ziclumeran (lonvo-z)
- Phase Of Trial
- Phase 3
- P value
- <0.0001
- Patients enrolled
- 80
- Attack free rate lonvo z
- 62%
- Attack free rate placebo
- 11%
- Attack reduction percent
- 87%
- Mean monthly attacks lonvo z
- 0.26
- Mean monthly attacks placebo
- 2.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.